Structural variation in amyloid-β fibrils from Alzheimer's disease clinical subtypes
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Aggregation of amyloid-β peptides into fibrils or other self-assembled states is central to the pathogenesis of Alzheimer’s disease. Fibrils formed in vitro by 40- and 42-residue amyloid-β peptides (Aβ40 and Aβ42) are polymorphic, with variations in molecular structure that depend on fibril growth conditions. Recent experiments suggest that variations in amyloid-β fibril structure in vivo may correlate with variations in Alzheimer’s disease phenotype, in analogy to distinct prion strains that are associated with different clinical and pathological phenotypes. Here we investigate correlations between structural variation and Alzheimer’s disease phenotype using solid-state nuclear magnetic resonance (ssNMR) measurements on Aβ40 and Aβ42 fibrils prepared by seeded growth from extracts of Alzheimer’s disease brain cortex. We compared two atypical Alzheimer’s disease clinical subtypes—the rapidly progressive form (r-AD) and the posterior cortical atrophy variant (PCA-AD)—with a typical prolonged-duration form (t-AD). On the basis of ssNMR data from 37 cortical tissue samples from 18 individuals, we find that a single Aβ40 fibril structure is most abundant in samples from patients with t-AD and PCA-AD, whereas Aβ40 fibrils from r-AD samples exhibit a significantly greater proportion of additional structures. Data for Aβ42 fibrils indicate structural heterogeneity in most samples from all patient categories, with at least two prevalent structures. These results demonstrate the existence of a specific predominant Aβ40 fibril structure in t-AD and PCA-AD, suggest that r-AD may relate to additional fibril structures and indicate that there is a qualitative difference between Aβ40 and Aβ42 aggregates in the brain tissue of patients with Alzheimer’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The oscillatory nature of the transferred 13C and 15N polarization is significantly damped by strong 1H-1H spin diffusion and T1ρ relaxation mechanisms, which leads to incomplete polarization transfer from 1H to 13C and 15N61.”
From Multi-receiver solid-state NMR using polarization optimized experiments (POE) at ultrafast magic angle spinning (2020) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD
Collinge, J., Sidle, K. C. L., Meads, J., Ironside, J., & Hill, A. F. (1996) · Nature · doi:10.1038/383685a0 · Cited by 1,735
Self-citationSelf-Propagating, Molecular-Level Polymorphism in Alzheimer's ß-Amyloid Fibrils
Petkova, A. T., Leapman, R. D., Guo, Z., Yau, W.-M., Mattson, M. P., & Tycko, R. (2005) · Science · doi:10.1126/science.1105850 · Cited by 1,687
Self-citationEight prion strains have PrPSc molecules with different conformations
Safar, J., Wille, H., Itri, V., Groth, D., Serban, H., Torchia, M., Cohen, F. E., & Prusiner, S. B. (1998) · Nature Medicine · doi:10.1038/2654 · Cited by 1,245
Molecular structural basis for polymorphism in Alzheimer's β-amyloid fibrils
Paravastu, A. K., Leapman, R. D., Yau, W.-M., & Tycko, R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806270105 · Cited by 1,160
Self-citationMolecular Structure of β-Amyloid Fibrils in Alzheimer’s Disease Brain Tissue
Lu, J.-X., Qiang, W., Yau, W.-M., Schwieters, C. D., Meredith, S. C., & Tycko, R. (2013) · Cell · doi:10.1016/j.cell.2013.08.035 · Cited by 1,097
Self-citationA General Model of Prion Strains and Their Pathogenicity
Collinge, J., & Clarke, A. R. (2007) · Science · doi:10.1126/science.1138718 · Cited by 1,057
Self-citationDistinct Tau Prion Strains Propagate in Cells and Mice and Define Different Tauopathies
Sanders, D. W., Kaufman, S. K., DeVos, S. L., Sharma, A. M., Mirbaha, H., Li, A., Barker, S. J., Foley, A. C., Thorpe, J. R., Serpell, L. C., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.04.047 · Cited by 986
Exogenous Induction of Cerebral ß-Amyloidogenesis Is Governed by Agent and Host
Meyer-Luehmann, M., Coomaraswamy, J., Bolmont, T., Kaeser, S., Schaefer, C., Kilger, E., Neuenschwander, A., Abramowski, D., Frey, P., Jaton, A. L., et al. (2006) · Science · doi:10.1126/science.1131864 · Cited by 971 · cited 2×
“Aβ (1-40) fibril polymorphism implies diverse interaction patterns in amyloid fibrils.”
Xiao, Y., Ma, B., McElheny, D., Parthasarathy, S., Long, F., Hoshi, M., Nussinov, R., & Ishii, Y. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2991 · Cited by 818
Atomic Resolution Structure of Monomorphic Aβ42 Amyloid Fibrils
Colvin, M. T., Silvers, R., Ni, Q. Z., Can, T. V., Sergeyev, I., Rosay, M., Donovan, K. J., Michael, B., Wall, J., Linse, S., et al. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b05129 · Cited by 809
Cited by
Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases
Soto, C., & Pritzkow, S. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0235-9 · Cited by 1,180
Fibril structure of amyloid-β(1–42) by cryo–electron microscopy
Gremer, L., Schölzel, D., Schenk, C., Reinartz, E., Labahn, J., Ravelli, R. B. G., Tusche, M., Lopez-Iglesias, C., Hoyer, W., Heise, H., et al. (2017) · Science · doi:10.1126/science.aao2825 · Cited by 1,041
A new era for understanding amyloid structures and disease
Iadanza, M. G., Jackson, M. P., Hewitt, E. W., Ranson, N. A., & Radford, S. E. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0060-8 · Cited by 980
Nguyen, P. H., Ramamoorthy, A., Sahoo, B. R., Zheng, J., Faller, P., Straub, J. E., Dominguez, L., Shea, J.-E., Dokholyan, N. V., De Simone, A., et al. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01122 · Cited by 678
Croissant, J. G., Fatieiev, Y., Almalik, A., & Khashab, N. M. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201700831 · Cited by 594
Half a century of amyloids: past, present and future
Ke, P. C., Zhou, R., Serpell, L. C., Riek, R., Knowles, T. P. J., Lashuel, H. A., Gazit, E., Hamley, I. W., Davis, T. P., Fändrich, M., et al. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00199a · Cited by 568
Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease
Roy, E. R., Wang, B., Wan, Y.-W., Chiu, G., Cole, A., Yin, Z., Propson, N. E., Xu, Y., Jankowsky, J. L., Liu, Z., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133737 · Cited by 563
“In AD brain, Aβ plaques are structurally and biochemically heterogeneous (12, 13).”
BackgroundZhang, M., Ma, Y., Ye, X., Zhang, N., Pan, L., & Wang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01464-x · Cited by 522
Secondary nucleation in amyloid formation
Törnquist, M., Michaels, T. C. T., Sanagavarapu, K., Yang, X., Meisl, G., Cohen, S. I. A., Knowles, T. P. J., & Linse, S. (2018) · Chemical Communications · doi:10.1039/c8cc02204f · Cited by 467
Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases
Jucker, M., & Walker, L. C. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0238-6 · Cited by 450
Amyloid fibril structure of α-synuclein determined by cryo-electron microscopy
Li, Y., Zhao, C., Luo, F., Liu, Z., Gui, X., Luo, Z., Zhang, X., Li, D., Liu, C., & Li, X. (2018) · Cell Research · doi:10.1038/s41422-018-0075-x · Cited by 437
Ramzan, F., Khan, M. U. G., Rehmat, A., Iqbal, S., Saba, T., Rehman, A., & Mehmood, Z. (2020) · Journal of Medical Systems · doi:10.1007/s10916-019-1475-2 · Cited by 432
A clinicopathological approach to the diagnosis of dementia
Elahi, F. M., & Miller, B. L. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.96 · Cited by 412
Amyloid-β and tau complexity — towards improved biomarkers and targeted therapies
Polanco, J. C., Li, C., Bodea, L.-G., Martinez-Marmol, R., Meunier, F. A., & Götz, J. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.162 · Cited by 378
Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
Arndt, J. W., Qian, F., Smith, B. A., Quan, C., Kilambi, K. P., Bush, M. W., Walz, T., Pepinsky, R. B., Bussière, T., Hamann, S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24501-0 · Cited by 365
Dynamics of oligomer populations formed during the aggregation of Alzheimer’s Aβ42 peptide
Michaels, T. C. T., Šarić, A., Curk, S., Bernfur, K., Arosio, P., Meisl, G., Dear, A. J., Cohen, S. I. A., Dobson, C. M., Vendruscolo, M., et al. (2020) · Nature Chemistry · doi:10.1038/s41557-020-0452-1 · Cited by 339
Propagation of Protein Aggregation in Neurodegenerative Diseases
Vaquer-Alicea, J., & Diamond, M. I. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045049 · Cited by 310
Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease
Villegas, S., Roda, A., Serra-Mir, G., Montoliu-Gaya, L., & Tiessler, L. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.332127 · Cited by 306
Challenges and hopes for Alzheimer’s disease
Tatulian, S. A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.01.016 · Cited by 291
Molecular pathology of neurodegenerative diseases by cryo-EM of amyloids
Scheres, S. H. W., Ryskeldi-Falcon, B., & Goedert, M. (2023) · Nature · doi:10.1038/s41586-023-06437-2 · Cited by 288
A computational model of neurodegeneration in Alzheimer’s disease
Jones, D., Lowe, V., Graff-Radford, J., Botha, H., Barnard, L., Wiepert, D., Murphy, M. C., Murray, M., Senjem, M., Gunter, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29047-4 · Cited by 78
Bamberger, C., Pankow, S., Martínez-Bartolomé, S., Ma, M., Diedrich, J., Rissman, R. A., & Yates, J. R. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00912 · Cited by 70
In-Cell Sensitivity-Enhanced NMR of Intact Viable Mammalian Cells
Ghosh, R., Xiao, Y., Kragelj, J., & Frederick, K. K. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c06680 · Cited by 66
Modulation of β-Amyloid Fibril Formation in Alzheimer’s Disease by Microglia and Infection
Brown, M. R., Radford, S. E., & Hewitt, E. W. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.609073 · Cited by 67
Nan, K., Han, Y., Fang, Q., Huang, C., Yu, L., Ge, W., Xiang, F., Tao, Y.-X., Cao, H., & Li, J. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2018.12.027 · Cited by 62
Integrative Structural Biology in the Era of Accurate Structure Prediction
Masrati, G., Landau, M., Ben-Tal, N., Lupas, A., Kosloff, M., & Kosinski, J. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167127 · Cited by 53
Distinct populations of highly potent TAU seed conformers in rapidly progressing Alzheimer’s disease
Kim, C., Haldiman, T., Kang, S.-G., Hromadkova, L., Han, Z. Z., Chen, W., Lissemore, F., Lerner, A., de Silva, R., Cohen, M. L., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abg0253 · Cited by 55
Derakhshankhah, H., Sajadimajd, S., Jafari, S., Izadi, Z., Sarvari, S., Sharifi, M., Falahati, M., Moakedi, F., Muganda, W. C. A., Müller, M., et al. (2020) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2020.102149 · Cited by 48
Weismiller, H. A., Murphy, R., Wei, G., Ma, B., Nussinov, R., & Margittai, M. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005316 · Cited by 44
Chen, Y.-Y., Wang, M.-C., Wang, Y.-N., Hu, H.-H., Liu, Q.-Q., Liu, H.-J., & Zhao, Y.-Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-00218-z · Cited by 33
Predicting Conversion from MCI to AD Combining Multi-Modality Data and Based on Molecular Subtype
Li, H.-T., Yuan, S.-X., Wu, J.-S., Gu, Y., & Sun, X. (2021) · Brain Sciences · doi:10.3390/brainsci11060674 · Cited by 27
“More and more studies, such as clinicopathologic [6], atrophy patterns on magnetic resonance imaging (MRI) [7] and amyloid-β fibril polymorphism on solid-state nuclear magnetic resonance (ssNMR) [8], have paid attention to the heterogeneity of AD.”
BackgroundYang, H., Yuan, P., Wu, Y., Shi, M., Caro, C. D., Tengeiji, A., Yamanoi, S., Inoue, M., DeGrado, W. F., & Condello, C. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2300769120 · Cited by 19
Maxwell, A. M., Yuan, P., Rivera, B. M., Schaaf, W., Mladinov, M., Prasher, V. P., Robinson, A. C., DeGrado, W. F., & Condello, C. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01298-0 · Cited by 23
Gopinath, T., & Veglia, G. (2020) · Journal of Magnetic Resonance · doi:10.1016/j.jmr.2019.106664 · Cited by 18
Bao, J., Chang, C., Zhang, Q., Saykin, A. J., Shen, L., Long, Q., & Initiative, F. T. A. D. N. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad073 · Cited by 16
Costello, W. N., Xiao, Y., Mentink-Vigier, F., Kragelj, J., & Frederick, K. K. (2024) · Journal of Biomolecular NMR · doi:10.1007/s10858-024-00436-9 · Cited by 16
Younas, A., Younas, N., Iqbal, M. J., Ferrer, I., & Zerr, I. (2024) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12964 · Cited by 16
Martá-Ariza, M., Leitner, D. F., Kanshin, E., Suazo, J., Giusti Pedrosa, A., Thierry, M., Lee, E. B., Devinsky, O., Drummond, E., Fortea, J., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02844-z · Cited by 15
Atomic-level differences between brain parenchymal- and cerebrovascular-seeded Aβ fibrils
Scherpelz, K. P., Wang, S., Pytel, P., Madhurapantula, R. S., Srivastava, A. K., Sachleben, J. R., Orgel, J., Ishii, Y., & Meredith, S. C. (2021) · Scientific Reports · doi:10.1038/s41598-020-80042-5 · Cited by 12
Gopinath, T., Weber, D. K., & Veglia, G. (2020) · Journal of Biomolecular NMR · doi:10.1007/s10858-020-00316-y · Cited by 14
Wang, S., Gopinath, T., & Veglia, G. (2019) · Journal of Biomolecular NMR · doi:10.1007/s10858-019-00273-1 · Cited by 6
(2021) · Annual Reports on NMR Spectroscopy · doi:10.1016/bs.arnmr.2020.10.003 · Cited by 5
Metadata
- Authors
- Qiang, W., Yau, W.-M., Lu, J.-X., Collinge, J., & Tycko, R.
- Venue
- Nature
- Published
- 2017-01
- Volume
- 541
- Issue
- 7636
- Pages
- 217-221
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2571390534
- Cited by
- 630
- References
- 30
- FWCI
- 47.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.